Targeting MYC – trick or treat?
Trick or Treat?
For the last two years we have head much about our ability to drug intractable targets, with KRAS G12C being the first to fall and other similar mutations now firmly in many companies sights.
What if we were to consider going beyond KRAS and targeting another of the four horsemen of the apocalypse?
The count is still out on TP53 and β-catenin, while MYC was long thought to be the scariest and most difficult to consider for numerous reasons.
We’re interrupting our SITC Preview series to switch horses and highlight some important developments coming out of Europe this week.
In this post we highlight several new preclinical and clinical developments relating to the MYC oncogene, which includes some candid expert commentary from an expert in the field…
To continue reading our latest discussion on oncology new product development plus expert commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
